OncoResponse Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Series 2
- Latest Deal Amount
-
$6M
- Investors
-
25
OncoResponse General Information
Description
Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition. The company leverages a proprietary B-cell technology platform to develop cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system, helping doctors and patients to combat cancer optimally.
Contact Information
Website
www.oncoresponse.comCorporate Office
- 609 Main Street
- Suite 4200
- Houston, TX 77002
- United States
Corporate Office
- 609 Main Street
- Suite 4200
- Houston, TX 77002
- United States
OncoResponse Timeline
OncoResponse Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series 2) | 06-May-2025 | $6M | Completed | Clinical Trials - Phase 2 | ||
| 7. Grant | 13-Jun-2023 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC (Series D) | 01-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 5. General Corporate Purpose | 15-Feb-2022 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series C) | 25-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 14-Jun-2019 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 23-Mar-2017 | $29.5M | $29.5M | Completed | Pre-Clinical Trials | |
| 1. Joint Venture | 18-Aug-2015 | Completed | Startup |
OncoResponse Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
OncoResponse Comparisons
Industry
Financing
Details
OncoResponse Competitors (107)
One of OncoResponse’s 107 competitors is RootPath, a Venture Capital-Backed company based in Framingham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| RootPath | Venture Capital-Backed | Framingham, MA | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Geneos Therapeutics | Venture Capital-Backed | Philadelphia, PA |
OncoResponse Patents
OncoResponse Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4695304-A2 | Lilrb2/1 antibody products and methods | Pending | 13-Apr-2023 | ||
| US-20250002577-A1 | Lilrb2/1 antibody products and methods | Pending | 13-Apr-2023 | ||
| WO-2024216139-A2 | Lilrb2/1 antibody products and methods | Inactive | 13-Apr-2023 | ||
| WO-2024216139-A3 | Lilrb2/1 antibody products and methods | Inactive | 13-Apr-2023 | ||
| AU-2023365813-A1 | Lilrb2 antibody products and methods | Pending | 18-Oct-2022 | C07K16/2803 |
OncoResponse Signals
OncoResponse Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oxford Finance | Lender/Debt Provider | Minority | ||
| Cancer Prevention and Research Institute of Texas | Government | |||
| Bering Capital | Venture Capital | Minority | ||
| InterVest | Venture Capital | Minority | ||
| Magnetar Capital | Hedge Fund | Minority |
OncoResponse Acquisitions (1)
OncoResponse’s most recent deal was a Merger/Acquisition with Paganini Biopharma. The deal was made on 07-Nov-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Paganini Biopharma | 07-Nov-2017 | Merger/Acquisition | Buildings and Property |
OncoResponse FAQs
-
When was OncoResponse founded?
OncoResponse was founded in 2015.
-
Where is OncoResponse headquartered?
OncoResponse is headquartered in Houston, TX.
-
What is the size of OncoResponse?
OncoResponse has 11 total employees.
-
What industry is OncoResponse in?
OncoResponse’s primary industry is Drug Discovery.
-
Is OncoResponse a private or public company?
OncoResponse is a Private company.
-
What is OncoResponse’s current revenue?
The current revenue for OncoResponse is .
-
How much funding has OncoResponse raised over time?
OncoResponse has raised $180M.
-
Who are OncoResponse’s investors?
Oxford Finance, Cancer Prevention and Research Institute of Texas, Bering Capital, InterVest, and Magnetar Capital are 5 of 25 investors who have invested in OncoResponse.
-
Who are OncoResponse’s competitors?
RootPath, Aro Biotherapeutics, Marengo Therapeutics, AnTolRx, and Geneos Therapeutics are some of the 107 competitors of OncoResponse.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process